19 May 2023 • 1 minute read
Life sciences companies and the risks posed by the mifepristone litigation
In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward.
